Celator gets $32.5m in non-IPO stock sale
This article was originally published in Scrip
Executive Summary
Celator Pharmaceuticals raised $32.5 million from the final closing of a private placement of common stock and warrants to complete its 300-patient Phase III clinical trial for CPX-351 (cytarabine:daunorubicin) as a first-line therapy to treat secondary acute myeloid leukemia (AML) in patients between the ages of 60 and 75.